Sign In
Buy ELOX
$12.05
+0.300 (+2.55%)
At Close: Jun 26, 2026
Eloxx Pharmaceuticals Inc (NASDAQ: ELOX) Stock: Over 20% Decrease Explanation
02:16pm, Friday, 14'th May 2021
The stock price of Eloxx Pharmaceuticals Inc (NASDAQ: ELOX) decreased by over 20% during intraday trading. This is why it happened.
Eloxx Pharmaceuticals, Inc. Announces Pricing of Public Offering of Common Stock
07:00am, Friday, 14'th May 2021
WALTHAM, Mass., May 14, 2021 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (the “Company”) (Nasdaq: ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today announced
Eloxx Pharmaceuticals Reports First Quarter 2021 Financial and Operating Results and Provides Business Update
05:15pm, Thursday, 06'th May 2021
Acquisition of Zikani Therapeutics, Ribosomal Modulation Company; Combined Company Advancing Ribosomal RNA-Targeted Genetic Therapies
Eloxx Pharmaceuticals (ELOX) Is in Oversold Territory: What's Next?
09:01am, Tuesday, 20'th Apr 2021
Eloxx Pharmaceuticals (ELOX) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.
Eloxx Pharmaceuticals Stock Price Increased Over 15% Pre-Market: Why It Happened
08:40am, Thursday, 01'st Apr 2021
The stock price of Eloxx Pharmaceuticals (NASDAQ: ELOX) increased by over 15% pre-market. This is why it happened.
Eloxx Pharmaceuticals Acquires Zikani Therapeutics
07:45am, Thursday, 01'st Apr 2021
Combined Company to be Leader in Ribosomal RNA-Targeted Genetic Therapy Bringing Together Complementary Platforms
Eloxx Pharmaceuticals, Inc. (ELOX) CEO Greg Williams on Q4 2020 Results - Earnings Call Transcript
08:56pm, Thursday, 11'th Mar 2021
Eloxx Pharmaceuticals, Inc. (ELOX) CEO Greg Williams on Q4 2020 Results - Earnings Call Transcript
Eloxx Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial and Operating Results and Provides Business Update
04:01pm, Thursday, 11'th Mar 2021
We expect to report top line data from our Phase 2 cystic fibrosis clinical trials in the first half of this year
Eloxx Pharmaceuticals to Report Fourth Quarter and Full Year 2020 Financial Results and Provide Business Update on March 11, 2021
05:14pm, Thursday, 04'th Mar 2021
Company management to host a webcast and conference call to provide a business update and review financial results at 4:30 p.m. ET Company management to host a webcast and conference call to provide a
Eloxx Announces Publication of Scientific Manuscript on ELX-02 in the Journal of Clinical Pharmacology in Drug Development
07:00am, Tuesday, 26'th Jan 2021
Publication titled: “ A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Escalation Study to Evaluate the Safety and Pharmacokinetics of ELX-02 in Healthy Subjects”
Eloxx Announces Publication of Scientific Manuscript on ELX-02 in the Journal of Clinical Pharmacology
07:00am, Wednesday, 20'th Jan 2021
Publication titled: “Phase 1 Renal Impairment Trial Results Enable Targeted Individualized Dosing of ELX-02 in Nephropathic Cystinosis Patients” Publication titled: “Phase 1 Renal Impairment Tri
The CF Foundation's partial funding of the U.S. trial has been extended to partial funding of the global clinical trial program which includes Europe and Israel
Eloxx Pharmaceuticals (ELOX) in Focus: Stock Moves 6.9% Higher
09:47am, Wednesday, 16'th Dec 2020
Eloxx Pharmaceuticals (ELOX) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
Eloxx Pharmaceuticals to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference
11:30am, Wednesday, 18'th Nov 2020
WALTHAM, Mass., Nov. 18, 2020 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel therapeutic
Eloxx Pharmaceuticals, Inc. (ELOX) CEO Greg Williams on Q3 2020 Results - Earnings Call Transcript
03:30am, Saturday, 07'th Nov 2020
Eloxx Pharmaceuticals, Inc. (ELOX) CEO Greg Williams on Q3 2020 Results - Earnings Call Transcript
